KLK3 and metastatic neoplasm: ADT is the standard treatment for metastatic disease, but is also used at earlier stages as adjuvant and neoadjuvant therapy in men who require radical treatment for localised disease and for those with rising concentrations of prostate-specific antigen (PSA) who are at high risk of distant metastases.3